Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 219)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Glucagon |
Approved |
Phase 4 |
|
16941-32-5 |
|
Synonyms:
Glucagon
Glucagon (recombinant dna origin)
Glucagon recombinant
Glucagon, human
|
Glucagon, porcine
Glucagone
Glucagonum
|
|
2 |
|
Levodopa |
Approved |
Phase 4 |
|
59-92-7 |
6047 |
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-dopa
(-)-Dopa
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
23734-74-9
25525-15-9
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
3 Hydroxy L tyrosine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-dihydroxy-L-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxyphenylalanine (VAN)
3,4-Dihydroxyphenyl-L-alanine
34241-25-3
37830_FLUKA
3-Hydroxy-L-tyrosine
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
BIDD:GT0158
Bio-0575
Biodopa
bmse000322
BPBio1_000059
Brocadopa
BSPBio_000053
BSPBio_002354
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
Cerepap
CHEBI:15765
CHEMBL1009
CID6047
Cidandopa
component of Sinemet
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
DOPA
Dopaflex
Dopaidan
Dopal
Dopal-fher
Dopal-Fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
Eldopal
Eldopar
Eldopatec
EU-0100454
Eurodopa
Helfo DOPA
|
helfo-Dopa
Helfo-Dopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
IDI1_000452
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
IV Levodopa
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L 3,4 Dihydroxyphenylalanine
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
l)-L-alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-dihydroxyphenylalanine
L-3,4-Dihydroxyphenylalanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
L-O-Dihydroxyphenylalanine
L-o-Hydroxytyrosine
Lopac0_000454
Lopac-D-9628
LS-255
L-β-(3,4-dihydroxyphenyl)alanine
Maipedopa
medphano Brand OF levodopa
MLS000028514
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
nchembio.2007.55-comp26
nchembio.89-comp9
ne
NINDS_000452
NSC 118381
NSC118381
Parda
Pardopa
PDSP1_001541
PDSP2_001525
Prestwick_185
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prodopa
Ro 4-6316
Roberts brand OF levodopa
Roche brand OF levodopa
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
Sobiodopa
SPBio_000391
SPBio_001974
Spectrum_000454
Spectrum2_000496
SPECTRUM2300205
Spectrum4_000539
Spectrum5_001899
Syndopa
UNII-46627O600J
Veldopa
Weldopa
β-(3,4-dihydroxyphenyl)alanine
β-(3,4-dihydroxyphenyl)-L-alanine
|
|
3 |
|
Bismuth subsalicylate |
Approved, Vet_approved |
Phase 4 |
|
14882-18-9 |
53629521 |
Synonyms:
2-Hydroxy-benzo[1,3,2]dioxabismin-4-one
Basic bismuth salicylate
Basic bismuth salicylic acid
Bismuth
Bismuth oxide salicylate
Bismuth oxide salicylic acid
Bismuth oxysalicylate
Bismuth oxysalicylic acid
Bismuth Subsalicylate
Bismuth subsalicylic acid
|
Bismuth(III) subsalicylate
Bismuthi subsalicylas
Bismutum subsalicylicum
Helidac
Kaopectate
pepto-Bismol
Pink bismuth
Subsalicylate bismuth
Trigastronol
Wismutsubsalicylat
|
|
4 |
|
Omeprazole |
Approved, Investigational, Vet_approved |
Phase 4 |
|
73590-58-6 |
4594 |
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
2,3,5-Trimethylpyridine/Omeprazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Antra
Antra mups
Antra MUPS
Audazol
Aulcer
AULCER
Axagon
Belmazol
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
D00455
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
esomeprazol
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-7629
Lucen
Magnesium, omeprazole
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
|
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole pellets
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec otc
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
Sodium, omeprazole
SPBio_002306
STK623746
Tedec ulceral
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
5 |
|
Esomeprazole |
Approved, Investigational |
Phase 4 |
|
161796-78-7, 119141-88-7, 161973-10-0 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(-)-omeprazole
(−)-omeprazole
(-)-Omeprazole
(-)-Omeprazole magnesium
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(s)-omeprazole
(S)-omeprazole
(S)-Omeprazole
(S)-Omeprazole magnesium
119141-88-7
119141-89-8
131959-78-9
161973-10-0
172964-80-6
193469-77-1
1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, magnesium salt, trihydrate
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
202742-32-3
217087-09-7
302841-07-2
320416-93-1
326602-80-6
371759-50-1
372519-57-8
376628-34-1
5-methoxy-1H-1,3-benzimidazol-2-yl (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl sulfoxide
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, magnesium salt (2:1), trihydrate
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
95382-33-5
AC1L1IIJ
AC1L2XM7
AC1L2XMA
AC1NSJYQ
AC-401
AC-402
AGI-010
AKOS005066653
Alenia
Antra
Antra MUPS
AstraZeneca brand OF esomeprazole magnesium
Audazol
AULCER
Axagon
Belmazol
BIDD:GT0020
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID130564
CID130565
CID4594
CID9568613
CID9568614
CID9579578
CPD000058847
D00455
D01984
D05259
D07917
D-961H
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Escz
Esofag
esomeprazol
Esomeprazol
esomeprazole
Esomeprazole
Ésoméprazole
Esomeprazole (INN)
Esomeprazole [INN:BAN]
Esomeprazole magnesium
Esomeprazole magnesium (USAN)
Esomeprazole magnesium hydrate
Esomeprazole magnesium hydrate (JAN)
Esomeprazole magnesium trihydrate
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole Sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
esomeprazolum
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H 199/18
H168/68
H-168/68
H199/18
H-199/18
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
I06-1976
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
|
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
KS-1054
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-181810
LS-185188
LS-7629
Lucen
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide trihydrate
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001165732
MLS001424148
MolPort-002-885-822
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-940-841
MolPort-005-943-880
Mopral
Morecon
N Bis (1H-Benzimidazole,5-methoxy-2-[(S)-[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl]-)
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium (TN)
Nexium Control
Nexium IV
Nexium, Esomeprazole magnesium
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole S-form
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec OTC
Prilosec OTC (TN)
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
S1743_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
SMR000550477
SPBio_002306
ST51053319
STK623746
Strontium, esomeprazole
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UNII-N3PA6559FT
UNII-R6DXU4WAY9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
ZINC04693574
ZINC04693575
Zoltum
|
|
6 |
|
Carbidopa |
Approved |
Phase 4 |
|
28860-95-9 |
34359 |
Synonyms:
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamate
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamic acid
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamate
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoate
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
(S)-(-)-carbidopa
(S)-(−)-carbidopa
(S)-(-)-Carbidopa
(S)-(-)-carbidopa hydrate
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-Carbidopa
(S)-carbidopa hydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C126_SIGMA
C1335_SIGMA
carbidopa
Carbidopa
Carbidopa (anhydrous)
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa Monohydrate
Carbidopa, (R)-isomer
Carbidopa, (S)-isomer
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
|
Carbidopum
Carbidopum [INN-Latin]
carbidopum monohydricum
CCRIS 5093
C-DOPA
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
DB00190
EINECS 249-271-9
EU-0100382
Hadrazino-alpha-methyldopa
HMS2089B12
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionate
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-a-Methyldopahydrazine
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
LS-77199
L-α-methyldopahydrazine
Methyldopahydrazine
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S(-)-CARBIDOPA
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
|
|
7 |
|
Trimethobenzamide |
Approved, Investigational |
Phase 4 |
|
138-56-7 |
5577 |
Synonyms:
N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
N-[[4-(2-Dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Tebamide
T-Gen
Ticon
|
Tigan
Trimethobenzamide
Trimethobenzamide monohydrochloride
Trimethobenzamidum
Trimetobenzamida
|
|
8 |
|
Apomorphine |
Approved, Investigational |
Phase 4 |
|
41372-20-7, 58-00-4 |
6005 |
Synonyms:
(−)-10,11-dihydroxyaporphine
(-)-10,11-Dihydroxyaporphine
(6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(6AR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-tetrahydro-6-Methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
314-19-2 (hydrochloride anhydrous)
41372-20-7 (hydrochloride hemihydrate)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, HCl, (R)-, hemihydrate
58-00-4
6abeta-Aporphine-10,11-diol
6a-beta-Aporphine-10,11-diol
6a-beta-Aporphine-10,11-diol, hydrochloride, hemihydrate
AC1L1LLC
Aguettant brand OF apomorphine hydrochloride
Anhydrous apomorphine hydrochloride
Anhydrous, apomorphine hydrochloride
Apokinon
Apokyn
Apomorfin
Apomorfina
Apomorphin
Apomorphin teclapharm
apomorphine
Apomorphine
Apomorphine (BAN)
Apomorphine chloride
Apomorphine HCl hydrate
Apomorphine hydrochloride
Apomorphine hydrochloride anhydrous
Apomorphine hydrochloride hemihydrate
Apomorphine hydrochloride, anhydrous
Apomorphine hydrochloride, hemihydrate
Apomorphinium chloride hemihydrate
Apomorphin-teclapharm
ApomorphinTeclapharm
Apormorphine
Biomol-NT_000019
BPBio1_000092
BPBio1_001179
BRD-K76022557-001-01-3
Britaject
|
Britannia brand OF apomorphine hydrochloride
BSPBio_000082
C17H17NO2
CE0800000
CHEBI:48538
Chloride, apomorphine
CID6005
D07460
DB00714
EINECS 200-360-0
Hemihydrate apomorphine hydrochloride
HMS2089C10
HSDB 3289
Hydrochloride anhydrous, apomorphine
Hydrochloride, anhydrous apomorphine
Hydrochloride, apomorphine
Hydrochloride, hemihydrate apomorphine
IV Apomorphine
Ixense
L-Apomorphine
LS-21474
NCGC00025349-01
NCGC00025349-02
nchembio.307-comp3
nchembio873-comp6
NIOSH/CE0800000
PDSP1_000780
PDSP2_001488
Prestwick0_000101
Prestwick1_000101
Prestwick2_000101
Prestwick3_000101
R-(−)-apomorphine
R-(-)-Apomorphine
SMP1_000027
SPBio_002021
STOCK1N-03149
Teclapharm brand OF apomorphine hydrochloride
Tocris-2073
UNII-N21FAR7B4S
Uprima
Uprima (TN)
VR004
VR-040
VR-400
|
|
9 |
|
Linaclotide |
Approved |
Phase 4 |
|
851199-59-2 |
65351 |
Synonyms:
2-10
5-13)
851199-59-2
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (disulfide bridge: 1-6
D09355
|
Linaclotida
Linaclotide
Linaclotide (USAN)
UNII-N0TXR0XR5X
|
|
10 |
|
Ticagrelor |
Approved |
Phase 4 |
|
274693-27-5 |
9871419 |
Synonyms:
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AZD 6140
AZD6140
|
AZD-6140
Brilinta
Brilique
Ticagrelor
|
|
11 |
|
Cangrelor |
Approved |
Phase 4 |
|
163706-06-7 |
9854012 |
Synonyms:
[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
|
|
|
12 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
13 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
14 |
|
Haloperidol |
Approved |
Phase 4 |
|
52-86-8 |
3559 |
Synonyms:
1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-fluoro-4-(4-(P-Chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
4'-fluoro-4-(4-Hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
5-21-02-00377 (Beilstein Handbook Reference)
52-86-8
AB00052008
AC-19691
AC1L1G7K
AC1Q77Z0
AKOS000280660
Aldo
ALDO
Aloperidin
Aloperidol
Aloperidolo
Aloperidolo [DCIT]
Aloperidolo [Italian]
Aloperidon
Apo-Haloperidol
BIDD:GT0128
Bio-0705
Biomol-NT_000035
Bioperidolo
BPBio1_000144
BPBio1_001231
BRD-K67783091-001-04-8
BRD-K67783091-001-05-5
BRN 0331267
Brotopon
BSPBio_000130
BSPBio_002096
C01814
C21H23ClFNO2
CAS-52-86-8
CCRIS 1630
CHEBI:5613
CHEMBL54
CID3559
cMAP_000037
D00136
D006220
DB00502
DivK1c_000654
Dozic
Dozix
Einalon S
EINECS 200-155-6
EU-0100583
Eukystol
Fortunan
g-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
Galoperidol
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
H 1512
H0912
H1512_SIGMA
Haldol
Haldol Decanoate
Haldol La
Haldol Solutab
Halidol
Halojust
Halol
Halopal
Haloperido
haloperidol
Haloperidol
Haloperidol (JP15/USP)
Haloperidol (JP15/USP/INN)
Haloperidol [USAN:INN:BAN:JAN]
Haloperidol Decanoate
Haloperidol Intensol
Haloperidol Lactate
Haloperidolum
Haloperidolum [INN-Latin]
Halopidol
Halopoidol
Halosten
HMS1568G12
HMS1920D03
HMS2089M15
HMS2091J09
|
HMS502A16
HSDB 3093
I14-13404
I14-14165
IDI1_000654
KBio1_000654
KBio2_001341
KBio2_002390
KBio2_003909
KBio2_004958
KBio2_006477
KBio2_007526
KBio3_001316
KBio3_002869
KBioGR_000980
KBioGR_002390
KBioSS_001341
KBioSS_002395
Keselan
L000288
Lealgin compositum
Lealgin Compositum
Linton
Lopac0_000583
Lopac-H-1512
LS-48311
McN-JR-1625
Mixidol
MLS000028450
MLS001146904
MolPort-000-883-311
NCGC00015500-01
NCGC00015500-02
NCGC00015500-06
NCGC00015500-14
NCGC00016234-01
NCGC00023875-02
NCGC00023875-04
NCGC00023875-05
NCGC00023875-06
NCGC00023875-07
NCGC00023875-08
NCGC00023875-09
NINDS_000654
Novo-Peridol
NSC 170973
NSC 615296
NSC170973
NSC615296
Oprea1_509923
Pekuces
Peluces
Peridol
Pernox
Pms Haloperidol
Prestwick_250
Prestwick0_000115
Prestwick1_000115
Prestwick2_000115
Prestwick3_000115
Probes1_000255
Probes2_000296
QTL1_000042
R 1625
R-1625
S1920_Selleck
Serenace
Serenase
Serenelfi
Sernas
Sernel
Sigaperidol
SMR000058303
SPBio_001236
SPBio_002069
Spectrum_000861
SPECTRUM1500325
Spectrum2_001268
Spectrum3_000448
Spectrum4_000570
Spectrum5_000788
Tocris-0931
Ulcolind
Uliolind
UNII-J6292F8L3D
Vesalium
WLN: T6NTJ A3VR DF& DQ DR DG
γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
γ-(4-(P-chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
|
|
15 |
|
Vitamin C |
Approved, Nutraceutical |
Phase 4 |
|
50-81-7 |
5785 54670067 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
30208-61-8
33034_RIEDEL
33034_SIAL
3-keto-L-Gulofuranolactone
3-Keto-L-gulofuranolactone
3-oxo-L-Gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AA
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
Acid Ascorbic
Acid, ascorbic
Acid, L-ascorbic
acide ascorbique
Acide ascorbique
Acide ascorbique [INN-French]
acido Ascorbico
Acido ascorbico
ácido ascórbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
acidum ascorbinicum
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
antiscorbic vita min
Antiscorbic vitamin
Antiscorbic Vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Antiscorbutic Vitamin
AR-1J3435
arco-Cee
Arco-cee
Arco-Cee
Ascoltin
Ascoltin (TN)
Ascorb
ascor-b.i.d
Ascor-b.i.d.
Ascor-B.I.D.
Ascorbajen
ascorbate
Ascorbate
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ascorbic acid
Ascorbic acid
Ascorbic Acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbic acid, monosodium salt
Ascorbic Acid, Monosodium Salt
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
bmse000182
BPBio1_000363
BSPBio_000329
C00072
C6H8O6
Cantan
Cantaxin
Caswell No. 061B
Catavin C
CCRIS 57
Ce lent
Ce Lent
Cebicure
Cebid
Cebion
Cebione
Cecon
cee-caps td
Cee-caps TD
Cee-Caps Td
Cee-Caps TD
Cee-vite
Cee-Vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Ce-Mi-Lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-Caps Tc
Cetane-Caps TC
Cetane-caps TD
Cetane-Caps Td
Cetane-Caps TD
Cetebe
Cetemican
Cevalin
|
Cevatine
Cevex
cevibid
Cevi-bid
Cevi-Bid
Cevimin
Ce-vi-sol
CE-VI-Sol
Cevital
Cevitamate
Cevitamic acid
Cevitamic Acid
Cevitamin
Cevitan
Cevitex
Cewin
CHEBI:29073
CHEMBL196
Chewcee
Ciamin
CID5785
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
Concemin
Cortalex
C-Quin
C-Span
C-Vimin
D00018
Davitamon C
DB00126
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
Hicee
HiCee
HSDB 818
Hybrin
ido-C
IDO-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina Askorbova
Kyselina askorbova [Czech]
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L-(+)-ascorbic acid
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-(+)-Ascorbic Acid
L-3-ketothreohexuronic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-ascorbate
L-Ascorbate
l-ascorbic acid
L-Ascorbic acid
L-Ascorbic Acid
L-Ascorbic acid, free radical form
Lemascorb
Liqui-cee
Liqui-Cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Lyxoascorbic Acid
LS-145
L-threo-ascorbic acid
L-threo-Ascorbic acid
L-Threoascorbic acid
l-threo-hex-1-eofuranos-3-ulose
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-hex-2-enono-1,4-lactone
L-Xyloascorbate
L-Xyloascorbic acid
L-Xyloascorbic Acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium Ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Meri-C
MLS002153776
MolPort-001-792-501
Monodehydroascorbic acid
Natrascorb
Natrascorb injectable
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
NCI-C54808
NSC 33832
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
roscorbi c
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
SMR001233160
Sodascorbate
Sodium ascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
vitamin C
Vitamin C
Vitamin- C
Vitamin-?C
Vitamina C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
|
|
16 |
|
Mosapride |
Investigational |
Phase 4 |
|
112885-41-3 |
|
17 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
18 |
|
Dihydroxyphenylalanine |
|
Phase 4 |
|
|
|
19 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
21 |
|
Emetics |
|
Phase 4 |
|
|
|
22 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
23 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
24 |
|
Carbidopa, levodopa drug combination |
|
Phase 4 |
|
|
|
25 |
|
Aromatic Amino Acid Decarboxylase Inhibitors |
|
Phase 4 |
|
|
|
26 |
|
Laxatives |
|
Phase 4 |
|
|
|
27 |
|
Cathartics |
|
Phase 4 |
|
|
|
28 |
|
Polyethylene glycol 3350 |
|
Phase 4 |
|
|
|
29 |
|
Purinergic P2Y Receptor Antagonists |
|
Phase 4 |
|
|
|
30 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
31 |
|
abobotulinumtoxinA |
|
Phase 4 |
|
|
|
32 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
33 |
|
Botulinum Toxins, Type A |
|
Phase 4 |
|
|
|
34 |
|
Botulinum Toxins |
|
Phase 4 |
|
|
|
35 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
36 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
37 |
|
Antiemetics |
|
Phase 4 |
|
|
|
38 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
39 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
40 |
|
Antacids |
|
Phase 4 |
|
|
|
41 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
42 |
|
Serotonin Receptor Agonists |
|
Phase 4 |
|
|
|
43 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
44 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
45 |
|
Opiate Alkaloids |
|
Phase 4 |
|
|
|
46 |
|
Haloperidol decanoate |
|
Phase 4 |
|
|
|
47 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
48 |
|
Granisetron |
Approved, Investigational |
Phase 3 |
|
109889-09-0 |
3510 |
Synonyms:
109889-09-0
1-Methyl-N-(endo-9-methyl-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
AC1NR4P1
APF530
BIDD:GT0272
BRL-43694
C07023
CHEMBL519643
CID5284566
D04370
granisetron
Granisetron
Granisetrón
|
Granisétron
Granisetron (USAN/INN)
Granisetron base
Granisetron HCl
Granisetron hydrochloride
Granisetron monohydrochloride
Granisetronum
Granisetronum [INN-Latin]
HMS2089P14
Hydrochloride, granisetron
Kytril
MolPort-005-943-366
Monohydrochloride, granisetron
Sancuso
|
|
49 |
|
Prucalopride |
Approved |
Phase 2, Phase 3 |
|
179474-81-8 |
|
Synonyms:
|
50 |
|
Erythromycin |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
114-07-8 |
12560 441411 |
Synonyms:
,10-dione
114-07-8
374700-25-1
3''-O-demethylerythromycin
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
45673_FLUKA
45674_FLUKA
79235-06-6
82343-12-2
A/T/S
Abboticin
Abomacetin
AC-12744
AC1L1FIQ
AC1L1QK7
AC1L1ZUR
AC1O8PVA
AC1Q2UA1
AC1Q6O1S
Acetate, epinephrine
Acneryne
Acnesol
adecane-2,10-dione (non-preferred name)
Adrenaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
AI3-50138
Ak-mycin
Ak-Mycin
Akne Cordes Losung
Aknederm Ery Gel
Aknemycin
Akne-Mycin
Akne-mycin (TN)
Aknin
Allergan brand OF adrenaline hydrochloride
AR-1A4414
AR-1H0723
AustriaS
BB_NC-1332
Benzamycin
Benzamycin Pak
BIDD:GT0017
bmse000664
BPBio1_000312
Bristamycin
BSPBio_000282
BSPBio_002480
C01912
C37H67NO13
CCRIS 9078
CHEBI:42355
CHEMBL532
CID12560
CID3255
CID6713919
CID8233
C-Solve-2
D00140
DB00199
Del-Mycin
Derimer
Deripil
DivK1c_000294
DivK1c_000397
DivK1c_000702
Dotycin
Dumotrycin
E- mycin, Erycin, Robimysin
E0751
E0774_SIAL
E5389_SIGMA
E6376_SIAL
E7904_SIGMA
E-Base
E-Base (base)
E-Glades
EINECS 204-040-1
EM
Emgel
EMU
Emu-V
Emu-Ve
Emuvin
Emycin
E-Mycin
E-Mycin (base)
Endoeritrin
Epifrin
Epinephrine
Epinephrine acetate
Epinephrine bitartrate
Epinephrine hydrochloride
Epinephrine hydrogen tartrate
Epitrate
Erecin
Erimycin-T
Erisone
Eritomicina
Eritrocina
Eritromicina
Eritromicina [INN-Spanish]
Ermycin
Eros
ERY
Eryacne
Eryacnen
Ery-B
Eryc
ERYC
ERYC (base)
Eryc (TN)
Eryc 125
Eryc Sprinkles
Eryc-125
Eryc-250
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erydermer
Ery-Diolan
Erygel
Erygel (TN)
Eryhexal
Erymax
Ery-maxin
Erymed
Erypar
Erysafe
Ery-Sol
Erytab
Ery-Tab
Ery-Tab (base)
Erythra-Derm
erythro
Erythro
Erythrocin
Erythrocin Stearate
Erythroderm
Erythrogran
Erythroguent
Erythromast 36
Erythromid
erythromycin
Erythromycin
|
Erythromycin & VRC3375
Erythromycin (JP15/USP/INN)
Erythromycin [INN:BAN:JAN]
Erythromycin A
Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279
Erythromycin B
Erythromycin base
Erythromycin C
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin intravenous
Erythromycin Lactate
Erythromycin lactobionate
Erythromycin Ointment
Erythromycin oxime
Erythromycin sodium lauryl sulfate
Erythromycin Stearate
ERYTHROMYCIN STEARATE
Erythromycin, compd. with monododecyl sulfate, sodium salt
Erythromycine
érythromycine
Erythromycine [INN-French]
Erythromycinum
Erythromycinum [INN-Latin]
Erythro-Statin
Erythro-Teva
Erytop
Erytrociclin
E-Solve 2
Ethril 250
ETS
HMS1568O04
HMS1920M04
HMS2091D05
HMS500O16
HSDB 3074
I06-0245
IDI1_000294
IDI1_000397
IDI1_000702
Ilocaps
Ilosone
Ilosone (estolate)
Iloticina
Ilotycin
Ilotycin Gluceptate
Ilotycin T.S
Ilotycin T.S.
Inderm
Inderm Gel
IndermRetcin
KBio1_000294
KBio1_000397
KBio1_000702
KBio2_000555
KBio2_001139
KBio2_003123
KBio2_003707
KBio2_005691
KBio2_006275
KBioGR_001175
KBioSS_000555
KBioSS_001139
Kesso-Mycin
KST-1A8261
L-Adrenaline hydrochloride
Latotryd
Lederpax
L-Epinephrine hydrochloride
LMPK04000006
LS-187077
LS-64648
Lyophrin
Medihaler-epi
Mephamycin
Mercina
MLS001066618
MolPort-000-772-161
MolPort-002-507-378
MolPort-003-933-429
NCGC00179619-01
nchembio.285-comp13
NCI-C55674
NINDS_000294
NINDS_000397
NINDS_000702
N-Methylerythromycin A
NSC 55929
NSC55929
Oftalmolosa Cusi Eritromicina
Oftamolets
Paediathrocin
Pantoderm
Pantodrin
Pantomicina
Pce
Pce (TN)
PCE Dispertab (base)
Pfizer-e
Pharyngocin
Prestwick_205
Prestwick0_000151
Prestwick1_000151
Prestwick2_000151
Prestwick3_000151
Primacine
Propiocine
Proterytrin
Retcin
Robimycin
Romycin
R-P Mycin
Sansac
Sans-acne
SBB057401
Serp-AFD
Skid Gel E
SMP1_000119
SMR000544946
SPBio_000778
SPBio_001226
SPBio_002221
Spectrum_000115
Spectrum_000659
SPECTRUM1500280
Spectrum2_000759
Spectrum2_001263
Spectrum4_000538
Spectrum5_001596
Staticin
Staticin (TN)
Stiemicyn
Stiemycin
STK249736
Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin
Taimoxin-F
Theramycin Z
Tiloryth
Tiprocin
Torlamicina
T-Stat
T-stat (TN)
Udima Ery Gel
UNII-63937KV33D
Wemid
Wyamycin S
|
|
Interventional clinical trials:
(show top 50)
(show all 349)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying |
Unknown status |
NCT02510976 |
Phase 4 |
prucalopride;placebo |
2 |
Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. |
Unknown status |
NCT02251249 |
Phase 4 |
Paracetamol concentration time curve from 0 to 120 min |
3 |
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 |
Unknown status |
NCT00473733 |
Phase 4 |
|
4 |
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis |
Unknown status |
NCT02264587 |
Phase 4 |
Mosapride;domperidone |
5 |
Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis |
Completed |
NCT00492622 |
Phase 4 |
Immediate-release omeprazole;Delayed-release omeprazole |
6 |
Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia |
Completed |
NCT00951431 |
Phase 4 |
Esomeprazole;Placebo |
7 |
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action |
Completed |
NCT01770145 |
Phase 4 |
APOKYN;L-dopa;Trimethobenzamide |
8 |
Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy: a Randomized Control Trial. |
Completed |
NCT03800745 |
Phase 4 |
Colace 100Mg Capsule;Miralax |
9 |
Single-dose Linaclotide for Capsule Endoscopy Preparation |
Completed |
NCT02465385 |
Phase 4 |
Linaclotide |
10 |
A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding |
Completed |
NCT01654770 |
Phase 4 |
|
11 |
PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study |
Completed |
NCT01788709 |
Phase 4 |
|
12 |
Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial |
Recruiting |
NCT01642875 |
Phase 4 |
|
13 |
Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit |
Recruiting |
NCT04210427 |
Phase 4 |
Polyethylene Glycol 3350 |
14 |
Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention |
Recruiting |
NCT04005729 |
Phase 4 |
Cangrelor 50 MG |
15 |
Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy |
Enrolling by invitation |
NCT03701919 |
Phase 4 |
Botulinum toxin pyloroplasty;Normal saline pyloric injection |
16 |
Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus |
Terminated |
NCT01286090 |
Phase 4 |
Cisapride;Placebo |
17 |
An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms |
Terminated |
NCT00390975 |
Phase 4 |
Tegaserod |
18 |
Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options |
Terminated |
NCT01281540 |
Phase 4 |
Cisapride;Placebo |
19 |
Enterra Therapy Gastric Stimulation System |
Terminated |
NCT00556166 |
Phase 4 |
|
20 |
Haloperidol vs Conventional Therapy for Gastroparesis |
Terminated |
NCT02057549 |
Phase 4 |
Haloperidol;Conventional Therapy |
21 |
Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis |
Withdrawn |
NCT01326117 |
Phase 4 |
tadalafil |
22 |
Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline) |
Withdrawn |
NCT01374828 |
Phase 4 |
Ketolorac |
23 |
A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers |
Withdrawn |
NCT00944593 |
Phase 4 |
|
24 |
Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial |
Unknown status |
NCT01460550 |
Phase 3 |
|
25 |
Role of Routine Nasogastric Decompression After Subtotal Gastrectomy |
Unknown status |
NCT00164918 |
Phase 3 |
|
26 |
Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. |
Unknown status |
NCT01989221 |
Phase 3 |
Sancuso® |
27 |
Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy |
Unknown status |
NCT02927886 |
Phase 3 |
|
28 |
Effect of Electroacupuncture in Diabetic Patients With Gastroparesis |
Unknown status |
NCT00227383 |
Phase 3 |
|
29 |
Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis |
Completed |
NCT02025751 |
Phase 3 |
Metoclopramide Nasal Spray;Placebo Nasal Spray |
30 |
Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis |
Completed |
NCT02025725 |
Phase 3 |
Metoclopramide Nasal Spray;Placebo Nasal Spray |
31 |
Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis |
Completed |
NCT00432835 |
Phase 3 |
|
32 |
Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients |
Completed |
NCT00738478 |
Phase 3 |
|
33 |
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) |
Completed |
NCT00765895 |
Phase 3 |
Nortriptyline Hydrochloride;Placebo (for nortriptyline) |
34 |
Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial |
Completed |
NCT02080754 |
Phase 3 |
|
35 |
Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial |
Completed |
NCT02031081 |
Phase 2, Phase 3 |
Prucalopride;Placebo |
36 |
Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility |
Completed |
NCT01379183 |
Phase 2, Phase 3 |
Erythromycin;Placebo |
37 |
A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy |
Completed |
NCT02250196 |
Phase 3 |
PEG-Asc;SPMC 2 |
38 |
Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations |
Completed |
NCT01563965 |
Phase 3 |
|
39 |
Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy |
Completed |
NCT02980562 |
Phase 3 |
Polyethylene Glycols;Bisacodyl |
40 |
Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation |
Completed |
NCT03074448 |
Phase 3 |
Sodium Picosulfate |
41 |
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis |
Recruiting |
NCT04028492 |
Phase 3 |
Tradipitant;Placebo |
42 |
Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula |
Recruiting |
NCT03419676 |
Phase 3 |
|
43 |
Treatment Protocol for the Compassionate Use of Domperidone |
Recruiting |
NCT01696734 |
Phase 3 |
Domperidone |
44 |
Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study |
Recruiting |
NCT03030170 |
Phase 3 |
|
45 |
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis |
Active, not recruiting |
NCT03383146 |
Phase 3 |
Relamorelin;Placebo |
46 |
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis |
Active, not recruiting |
NCT03426345 |
Phase 3 |
Relamorelin;Placebo |
47 |
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis |
Active, not recruiting |
NCT03285308 |
Phase 3 |
Relamorelin;Placebo |
48 |
Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis |
Active, not recruiting |
NCT03786380 |
Phase 3 |
Relamorelin 10 μg |
49 |
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis |
Enrolling by invitation |
NCT03420781 |
Phase 3 |
Relamorelin;Placebo |
50 |
A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis. |
Suspended |
NCT00470795 |
Phase 3 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cisapride
Metoclopramide
|
Metoclopramide Hydrochloride
|
Cochrane evidence based reviews: gastroparesis
|